FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmacology and medicine and concerns an immunostimulating composition, and methods for using it for enhancing the immune response, particularly for treating infections caused by bacterial and viral pathogens, to adjuvant compositions and methods for enhancing the antigen immunogenicity when used as an adjuvant of vaccines. The pharmaceutical composition of pattern-recognising receptor ligands contains muramyl peptide of structural formula N-acetylmuramyl-L-alanyl-D-isoglutamine and lipopolysaccharide or lipid A in the following proportions, wt %: muramyl peptide of structural formula N-acetylmuramyl-L-alanyl-D-isoglutamine 0.00001 to 0.01, lipopolysaccharide or lipid A 0.00001 to 0.01, a solvent - the rest.
EFFECT: group of inventions provides high immunostimulating activity and prolonged action of the composition.
7 cl, 5 ex, 1 tbl, 9 dwg
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION BASED ON PLGA FOR THE INDUCTION OF THE EFFECTIVE MUCOSAL IMMUNE RESPONSE | 2018 |
|
RU2742580C2 |
PHARMACEUTICAL COMPOSITION OF IMMUNOSTIMULATING SUBSTANCES OF MURAMYLPEPTIDE NATURE | 2021 |
|
RU2768484C1 |
RECOMBINANT TRIVALENT INFLUENZA VACCINE | 2012 |
|
RU2485973C1 |
VACCINE COMPOSITION | 2013 |
|
RU2655627C2 |
BROAD-SPECTRUM M2 PROTEIN ECTODOMAIN AVIAN INFLUENZA TYPE A VACCINE | 2014 |
|
RU2571944C1 |
USE OF MONOMYCOLYL GLYCEROL (MMG) AS ADJUVANT | 2008 |
|
RU2479317C2 |
COMPOSITION FOR AMPLIFICATION OF TRANSGENE EXPRESSION IN EUCARIOTIC CELLS, AND METHOD FOR INCREASING GENERATION OF TARGET PROTEIN CODED WITH TRANSGENE | 2013 |
|
RU2546249C2 |
IMMUNOBIOLOGICAL AGENT FOR TREATING URINARY BLADDER CANCER AND METHOD OF APPLICATION THEREOF | 2013 |
|
RU2555327C2 |
MULTICOMPONENT VACCINE FOR IMMUNOPROPHYLAXIS AND IMMUNOTHERAPY OF DISEASES CAUSED BY OPPORTUNISTIC PATHOGENS | 2022 |
|
RU2786222C1 |
POLYANTIGENIC VACCINE FOR PREVENTING AND ADJUNCTIVE TREATMENT OF TUBERCULOSIS | 2019 |
|
RU2724896C1 |
Authors
Dates
2013-11-10—Published
2012-07-20—Filed